FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
vvasi ii iytori,	D.C.	20349

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MCCLUSKI STEPHEN C				2. Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc. [IMGN]								(Ch	elationship o eck all applio X Directo	,					
	MUNOGEN	I, INC.	(Middle)			Date of /15/20		Trans	saction (Month/Day/Year)					Officer below)	(give title		Other (s below)	specify	
830 WINTER STREET					4. I	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) WALTH	AM M	ΊΑ	02451											X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																
		Tab	le I - Non	-Deriv	ative	e Sec	curities	s Ac	quired, Di	ispose	d of	f, or Ber	neficiall	y Owned					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				Execution Date,			Code (Ins						es F ally (I Following (I	Form (D) o	6. Ownership Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code V	Amo	unt	(A) or (D)	Price		ransaction(s) nstr. 3 and 4)			(Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
			ransa Code (I	ansaction of E ode (Instr. Derivative (N			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)			10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				c	Code	v	(A)	(D)	Date Exercisable	Expirati Date		Title	Amount or Number of Shares						
Deferred Share Unit	\$0 ⁽¹⁾	06/15/2022			A		15,000		(2)(3)	(3)		Common Stock ⁽³⁾	15,000	\$0 ⁽¹⁾	105,45	58	D		
Stock Option (right to buy)	\$3.37	06/15/2022			A		44,000		(4)	06/15/20	032	Common Stock	44,000	\$3.37	44,00	0	D		

Explanation of Responses:

- 1. The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.
- 2. The deferred share units vest ratably over a one-year period in quarterly increments beginning on 9/1/22, contingent upon the individual remaining a director as of each vesting date.
- 3. The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.
- 4. Exercisable as to 11,000 shares on each of 9/1/22, 12/1/22, 3/1/23, and 6/1/23, contingent upon the individual remaining a director as of each vesting date.

/s/ Renee Lentini, Attorney-in-

06/17/2022

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.